These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29408933)

  • 1. Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis.
    Nemtsova Y; Wiseman JA; El-Banna M; Lobel P; Sleat DE
    PLoS One; 2018; 13(2):e0192286. PubMed ID: 29408933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
    Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
    Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
    [No Abstract]   [Full Text] [Related]  

  • 3. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal protein thermal stability does not correlate with cellular half-life: global observations and a case study of tripeptidyl-peptidase 1.
    Collier AM; Nemtsova Y; Kuber N; Banach-Petrosky W; Modak A; Sleat DE; Nanda V; Lobel P
    Biochem J; 2020 Feb; 477(3):727-745. PubMed ID: 31957806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial genetic suppression of a loss-of-function mutant of the neuronal ceroid lipofuscinosis-associated protease TPP1 in Dictyostelium discoideum.
    Phillips JE; Gomer RH
    Dis Model Mech; 2015 Feb; 8(2):147-56. PubMed ID: 25540127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis.
    Wang YL; Zeng ZY; Song XW; Hao ZF; Shi YW; Tang B; Chen SQ; Gao MM; Di W; Long YS; Yi YH; Liao WP
    Neurogenetics; 2011 Feb; 12(1):93-5. PubMed ID: 20820830
    [No Abstract]   [Full Text] [Related]  

  • 7. Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation.
    Chen ZR; Liu DT; Meng H; Liu L; Bian WJ; Liu XR; Zhu WW; He Y; Wang J; Tang B; Su T; Yi YH
    Seizure; 2019 Jul; 69():180-185. PubMed ID: 31059981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene symbol: TPP1. Disease: Neuronal Ceroid Lipofuscinosis, late infantile.
    Kohan R; Muller VJ; Fietz MJ; Cismondi AI; Oller Ramírez AM; Halac IN
    Hum Genet; 2008 Jun; 123(5):553. PubMed ID: 20960655
    [No Abstract]   [Full Text] [Related]  

  • 9. Global Brain Transcriptome Analysis of a Tpp1 Neuronal Ceroid Lipofuscinoses Mouse Model.
    Domowicz MS; Chan WC; Claudio-Vázquez P; Henry JG; Ware CB; Andrade J; Dawson G; Schwartz NB
    ASN Neuro; 2019; 11():1759091419843393. PubMed ID: 31003587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease).
    Sun Y; Almomani R; Breedveld GJ; Santen GW; Aten E; Lefeber DJ; Hoff JI; Brusse E; Verheijen FW; Verdijk RM; Kriek M; Oostra B; Breuning MH; Losekoot M; den Dunnen JT; van de Warrenburg BP; Maat-Kievit AJ
    Hum Mutat; 2013 May; 34(5):706-13. PubMed ID: 23418007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
    Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
    Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.
    Chakrabarti S; Chandra S; Roy A; Dasarathi S; Kundu M; Pahan K
    Neurobiol Dis; 2019 Jul; 127():362-373. PubMed ID: 30928643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.
    Xu S; Wang L; El-Banna M; Sohar I; Sleat DE; Lobel P
    Mol Ther; 2011 Oct; 19(10):1842-8. PubMed ID: 21730969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier: Long-Term Efficacy, Toxicity, and Mechanism.
    Meng Y; Wiseman JA; Nemtsova Y; Moore DF; Guevarra J; Reuhl K; Banks WA; Daneman R; Sleat DE; Lobel P
    Mol Ther; 2017 Jul; 25(7):1531-1543. PubMed ID: 28456380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.
    Guhaniyogi J; Sohar I; Das K; Stock AM; Lobel P
    J Biol Chem; 2009 Feb; 284(6):3985-97. PubMed ID: 19038967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.
    Kohan R; Carabelos MN; Xin W; Sims K; Guelbert N; Cismondi IA; Pons P; Alonso GI; Troncoso M; Witting S; Pearce DA; Dodelson de Kremer R; Oller-Ramírez AM; Noher de Halac I
    Gene; 2013 Mar; 516(1):114-21. PubMed ID: 23266810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.
    Katz ML; Tecedor L; Chen Y; Williamson BG; Lysenko E; Wininger FA; Young WM; Johnson GC; Whiting RE; Coates JR; Davidson BL
    Sci Transl Med; 2015 Nov; 7(313):313ra180. PubMed ID: 26560358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses.
    Sima N; Li R; Huang W; Xu M; Beers J; Zou J; Titus S; Ottinger EA; Marugan JJ; Xie X; Zheng W
    Orphanet J Rare Dis; 2018 Apr; 13(1):54. PubMed ID: 29631617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.